| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8454737 | Lung Cancer | 2016 | 7 Pages |
Abstract
There is a higher incidence of brain metastases for patients with EGFR+ metastatic NSCLC, even when adjusted for differences in survival, compared to EGFR WT. For patients with and without brain metastases, survival prognosis with stage IV NSCLC is much longer with EGFR+ disease.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Fred Hsu, Alex De Caluwe, David Anderson, Alan Nichol, Ted Toriumi, Cheryl Ho,